Principal Financial Group Inc Kura Oncology, Inc. Transaction History

Principal Financial Group Inc

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 29, 2024	SELL	$17.53 - $22.98 $92,891 - $121,771	-5,299 Reduced 29.78%	12,492 $257,000
Q1 2024 Apr 29, 2024	SELL	$13.42 - $23.53 $21,176 - $37,130	-1,578 Reduced 8.15%	17,791 $379,000
Q4 2023 Feb 07, 2024	SELL	$7.58 - $14.38 $15,880 - $30,126	-2,095 Reduced 9.76%	19,369 $278,000
Q3 2023 Nov 02, 2023	BUY	$8.44 - $11.86 $32,721 - $45,981	3,877 Added 22.04%	21,464 $195,000
Q2 2023 Aug 07, 2023	BUY	$9.62 - $13.99 $3,857 - $5,609	401 Added 2.33%	17,587 $186,000
Q1 2023 May 09, 2023	BUY	$10.71 - $14.6 $27,546 - $37,551	2,572 Added 17.6%	17,186 $210,000
Q4 2022 Feb 09, 2023	BUY	$11.23 - $16.9 $4,020 - $6,050	358 Added 2.51%	14,614 $181,000
Q3 2022 Nov 09, 2022	BUY	$12.01 - $19.45 $41,650 - $67,452	3,468 Added 32.15%	14,256 $195,000
Q2 2022 Aug 10, 2022	BUY	$10.71 - $18.33 $115,539 - $197,744	10,788 New	10,788 $198,000
Q4 2021 Feb 09, 2022	SELL	$12.22 - $19.57 $160,741 - $257,423	-13,154 Closed	0 $0
Q3 2021 Nov 09, 2021	SELL	$15.42 - $21.72 $32,860 - $46,285	-2,131 Reduced 13.94%	13,154 $246,000
Q2 2021 Aug 10, 2021	SELL	$20.85 - $29.88 $224,346 - $321,508	-10,760 Reduced 41.31%	15,285 $318,000
Q1 2021 May 10, 2021	SELL	$24.75 - $39.14 $31,135 - $49,238	-1,258 Reduced 4.61%	26,045 $737,000
Q4 2020 Feb 08, 2021	BUY	$29.0 - $41.62 $278,255 - $399,343	9,595 Added 54.18%	27,303 $892,000
Q3 2020 Nov 06, 2020	BUY	$16.3 - $30.64 $288,640 - $542,573	17,708 New	17,708 $542,000

185

81.8M

42.1K

34K

Ticker KURA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,893,000
Market Cap $598M
Description
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.